🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months
đź”» The Study and Important Caveats:
Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey.
Among those 122 people:
84% said their cancer had either completely disappeared, shrunk, or stopped spreading.
About 33% reported “no evidence of disease”
About 16% reported the tumors got smaller
About 36% said the cancer stayed the same (stable)
16% said it got worse
Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine.
đź”» Important caveats:
• The results come only from patient surveys — no doctors independently checked scans or medical records.
• There was no control group to compare against.
• Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time.
• About 38% of the original group didn’t finish the survey.
• The journal later issued an official “Expression of Concern” and started an audit because of questions about the data.
• The authors say these findings are just a starting point and that proper clinical trials are still needed.
đź”»What kinds of cancer were included?
Most common
Prostate: 55 patients (27.9%)
Breast: 36 patients (18.3%)
Lung: 17 patients (8.6%)
Colon: 10 patients (5.1%)
Liver: 5 patients (2.5%)
Other cancers (74 patients / 37.6%)
Urologic (bladder & kidney): 9
Pancreatic & bile duct: 6
Hematologic (lymphoma): 5
Head, neck & oral: 5
Gynecologic (ovarian & uterine): 5
Thyroid: 4
Brain & neurological: 3
Multiple myeloma: 3
Melanoma (skin & ocular): 3
Sarcoma: 2
Miscellaneous/unspecified: 29
đź”»Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers.
Clip: https://rumble.com/shorts/v7eap08